trending Market Intelligence /marketintelligence/en/news-insights/trending/ZmO1WhNuAWORtKoxZwt6Jg2 content esgSubNav
In This List

Mayne Pharma skin disease drug gets expanded US FDA nod to treat adolescents

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps

Blog

Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge

Blog

Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally


Mayne Pharma skin disease drug gets expanded US FDA nod to treat adolescents

Mayne Pharma Group Ltd. said the U.S. Food and Drug Administration approved its Sorilux foam for treating plaque psoriasis in adolescents.

The therapy is now approved for treating plaque psoriasis of the scalp and body in patients aged 12 years and above. Sorilux was previously approved by the U.S. regulator for treating plaque psoriasis in patients aged 18 years and older.

The additional approval is based on further data obtained in a follow-on open-label study in psoriasis patients aged 12 to 17 years.

Psoriasis is an autoimmune disease — a condition where the immune system attacks healthy cells by mistake — of the skin which affects 7.5 million Americans annually. Plaque psoriasis affects about 80% of people with the disorder.

Australian drugmaker Mayne Pharma acquired Sorilux from GlaxoSmithKline PLC in 2016.